{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:11:16Z","timestamp":1789830676035,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012295","name":"Newcastle NIHR Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"publisher","award":["NIHR301627"],"award-info":[{"award-number":["NIHR301627"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>CYLD cutaneous syndrome (CCS) is caused by germline heterozygous pathogenic variants in CYLD and results in the progressive formation of cylindromas, spiradenomas or trichoepitheliomas. Malignant cylindroma is a rare skin adnexal tumour occurring in CCS, which can metastasize with lethal outcomes and has limited genomic characterization. BRCA2 loss in CCS is not described and may modulate the cutaneous cancer risk of CCS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To establish whether BRCA deficiency drives metastatic malignant cylindroma and to report the phenotype of three siblings with digenic inheritance of CYLD and BRCA2 pathogenic variants (PVs), one of whom developed metastatic cylindroma at 28\u2005years old.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A kindred study reporting seven members of a family with CCS was conducted in a tertiary hospital setting within the United Kingdom from April 2021 to February 2023. Clinical phenotype, pathological, radiological and genetic findings and treatment data were \u00adcollected. Whole-genome sequencing of the primary malignant cylindroma occurring in one patient was performed to identify targetable driver mutations and signatures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Malignant cylindroma arose in one (proband) of the two male siblings with digenic inheritance of BRCA2 (c.5158insT) and CYLD (c.2689-2A&amp;gt;G) pathogenic variants. A further female sibling with digenic inheritance of the same BRCA2 and CYLD PVs developed early breast cancer. Whole-genome sequencing of the primary malignant cylindroma in the affected patient showed loss of heterozygosity of both BRCA2 and CYLD. Bioinformatic analysis confirmed homologous repair deficiency (HRD). These data supported the use of the PARP [poly(ADP-ribose) polymerase] inhibitor rucaparib to target HRD in a non-canonical BRCA-deficient skin cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Digenic inheritance of pathogenic variants in cancer-predisposing genes should prompt clinicians to be vigilant for atypical malignant presentations. We demonstrate that rapid whole-genome sequencing can inform the treatment of metastatic malignant cylindroma and identify novel systemic therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf064","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:15:26Z","timestamp":1738671326000},"page":"1322-1329","source":"Crossref","is-referenced-by-count":4,"title":["Metastatic malignant cylindroma arising on a background of digenic inheritance of <i>BRCA2<\/i> and <i>CYLD<\/i> pathogenic variants targeted with PARP inhibition"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3564-4933","authenticated-orcid":false,"given":"William","family":"Fostier","sequence":"first","affiliation":[{"name":"Translational and Clinical Research\u202fInstitute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Husain","sequence":"additional","affiliation":[{"name":"Department of Pathology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Namini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Leeds Teaching Hospital , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leeds Teaching Hospital , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgie","family":"Holt","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research\u202fInstitute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Memari","sequence":"additional","affiliation":[{"name":"Academic Department of Medical Genetics, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Davies","sequence":"additional","affiliation":[{"name":"Academic Department of Medical Genetics, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene C C","family":"Koh","sequence":"additional","affiliation":[{"name":"Academic Department of Medical Genetics, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Nik-Zainal","sequence":"additional","affiliation":[{"name":"Academic Department of Medical Genetics, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5850-5680","authenticated-orcid":false,"given":"Neil","family":"Rajan","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research\u202fInstitute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"Department of Dermatology, Royal Victoria Infirmary , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025062505024585800_llaf064-B1","doi-asserted-by":"crossref","first-page":"109777","DOI":"10.1016\/j.celrep.2021.109777","article-title":"Regulation of CYLD activity and specificity by phosphorylation and ubiquitin-binding CAP-Gly domains","volume":"37","author":"Elliott","year":"2021","journal-title":"Cell Rep"},{"key":"2025062505024585800_llaf064-B2","doi-asserted-by":"crossref","first-page":"dmm.050093","DOI":"10.1242\/dmm.050093","article-title":"CYLD in health and disease","volume":"16","author":"Mar\u00edn-Rubio","year":"2023","journal-title":"Dis Model Mech"},{"key":"2025062505024585800_llaf064-B3","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/S1470-2045(15)00245-4","article-title":"Inherited cylindromas: lessons from a rare tumour","volume":"16","author":"Rajan","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025062505024585800_llaf064-B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/cdd.2009.43","article-title":"CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes","volume":"17","author":"Sun","year":"2010","journal-title":"Cell Death Differ"},{"key":"2025062505024585800_llaf064-B5","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1038\/s41467-019-12746-w","article-title":"Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Nat Commun"},{"key":"2025062505024585800_llaf064-B6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2025062505024585800_llaf064-B7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"2025062505024585800_llaf064-B8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025062505024585800_llaf064-B9","article-title":"The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations","volume":"22","author":"Narod","year":"2024","journal-title":"Hered Cancer Clin Pract"},{"key":"2025062505024585800_llaf064-B10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/cge.14231","article-title":"Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood","volume":"103","author":"Maxwell","year":"2023","journal-title":"Clin Genet"},{"key":"2025062505024585800_llaf064-B11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2007.08.009","article-title":"A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature","volume":"179","author":"Ghataorhe","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"2025062505024585800_llaf064-B12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-013-2538-6","article-title":"Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer","volume":"139","author":"Campos","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2025062505024585800_llaf064-B13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10689-016-9952-y","article-title":"Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor","volume":"16","author":"Goehringer","year":"2017","journal-title":"Fam Cancer"},{"key":"2025062505024585800_llaf064-B14","first-page":"e71310","article-title":"BRCA2 and TP53 mutations in a breast cancer patient: a case report and review of the literature","volume":"16","author":"Lopes Viana","year":"2024","journal-title":"Cureus"},{"key":"2025062505024585800_llaf064-B15","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/1097-0142(19930901)72:5<1618::AID-CNCR2820720521>3.0.CO;2-5","article-title":"Cutaneous cylindroma with malignant transformation","volume":"72","author":"Gerretsen","year":"1993","journal-title":"Cancer"},{"key":"2025062505024585800_llaf064-B16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/DAD.0b013e3181b9678c","article-title":"Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke\u2013Spiegler syndrome","volume":"32","author":"Kazakov","year":"2010","journal-title":"Am J Dermatopathol"},{"key":"2025062505024585800_llaf064-B17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"2025062505024585800_llaf064-B18","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl9283","article-title":"Substitution mutational signatures in whole-genome-sequenced cancers in the UK population","volume":"376","author":"Degasperi","year":"2022","journal-title":"Science"},{"key":"2025062505024585800_llaf064-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpra.2019.04.003","article-title":"Malignant cylindroma of the scalp treated with staged perimeter excision: a case report and literature review","volume":"21","author":"Kim","year":"2019","journal-title":"JPRAS Open"},{"key":"2025062505024585800_llaf064-B20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/PAS.0b013e3181966762","article-title":"Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke\u2013Spiegler syndrome","volume":"33","author":"Kazakov","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2025062505024585800_llaf064-B21","doi-asserted-by":"crossref","first-page":"e47290","DOI":"10.1371\/journal.pone.0047290","article-title":"Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses","volume":"7","author":"Le","year":"2012","journal-title":"PLoS One"},{"key":"2025062505024585800_llaf064-B22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2133.2001.04460.x","article-title":"Malignant transformation of multiple dermal cylindromas","volume":"145","author":"Durani","year":"2001","journal-title":"Br J Dermatol"},{"key":"2025062505024585800_llaf064-B23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijscr.2013.02.027","article-title":"Malign cylindroma of the scalp with multiple cervical lymph node metastasis: a case report","volume":"4","author":"Akgul","year":"2013","journal-title":"Int J Surg Case Rep"},{"key":"2025062505024585800_llaf064-B24","doi-asserted-by":"crossref","first-page":"jnccn.2021.7119","DOI":"10.6004\/jnccn.2021.7119","article-title":"Metastatic spiradenocarcinoma managed with PD-1 inhibition","volume":"20","author":"Wargo","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025062505024585800_llaf064-B25","doi-asserted-by":"crossref","first-page":"a004408","DOI":"10.1101\/mcs.a004408","article-title":"Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease","volume":"5","author":"Momen","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"2025062505024585800_llaf064-B26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"2025062505024585800_llaf064-B27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025062505024585800_llaf064-B28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12915-022-01316-0","article-title":"APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types","volume":"20","author":"Jakobsdottir","year":"2022","journal-title":"BMC Biol"},{"key":"2025062505024585800_llaf064-B29","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2018","journal-title":"Oncotarget"},{"key":"2025062505024585800_llaf064-B30","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-19-2786","article-title":"The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer","volume":"26","author":"Serebrenik","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025062505024585800_llaf064-B31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","article-title":"A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies","volume":"1","author":"Degasperi","year":"2020","journal-title":"Nat Cancer"},{"key":"2025062505024585800_llaf064-B32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: tumor suppressor and metabolic regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front Endocrinol"},{"key":"2025062505024585800_llaf064-B33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ncomms1776","article-title":"CYLD negatively regulates transforming growth factor-\u03b2-signalling via deubiquitinating Akt","volume":"3","author":"Lim","year":"2012","journal-title":"Nat Commun"},{"key":"2025062505024585800_llaf064-B34","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1038\/s41380-022-01571-1","article-title":"Cylindromatosis drives synapse pruning and weakening by promoting macroautophagy through Akt-mTOR signaling","volume":"27","author":"Zajicek","year":"2022","journal-title":"Mol Psychiatry"},{"key":"2025062505024585800_llaf064-B35","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3\u2005K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers"},{"key":"2025062505024585800_llaf064-B36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.molcel.2010.07.023","article-title":"STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer","volume":"39","author":"Iliopoulos","year":"2010","journal-title":"Mol Cell"},{"key":"2025062505024585800_llaf064-B37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3\u2005K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025062505024585800_llaf064-B38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF01826771","article-title":"Weitere Beitr\u00e4ge zur Kenntnis der sogenannten Zylindrome der Kopfhaut","volume":"159","author":"Wiedmann","year":"1930","journal-title":"Arch Dermatol Syph"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf064\/61770741\/llaf064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1322\/61770741\/llaf064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1322\/61770741\/llaf064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:02:58Z","timestamp":1750842178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/7\/1322\/8002766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf064","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,2,5]]}}}